Safety of human umbilical cord derived mesenchymal stem cells (HU - MSCs) infusion treatment of children refractory lung diseases

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800015735

Enrollment

Unknown

Registered

2018-04-17

Start date

2015-10-01

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children lung diseases

Interventions

one cohort:mesenchymal stem cells infusion

Eligibility

Sex/Gender

All

Age

0.5 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1. children refractory lung diseases; 2. cannot be healed by conventional drug therapy; 3. informed consent signed by parents and/or patients(>14years old).

Exclusion criteria

Exclusion criteria: 1. complex congenital heart disease; 2. WHO class III or IV pulmonary hypertension; 3. congenital respiratory tract malformations; 4. congenital anomaly of nervous system; 5. hereditary diseases; 6. HIV infected/viral hepatitis/tuberculosis/ syphilis; 7. severe or uncontrolled infection not expected to survive 2 weeks; 8. active pneumorrhagia or tension pneumothorax; 9. malignant diseases; 10. patient participating or having participated in a clinical trial with another investigation drugs.

Design outcomes

Primary

Measure	Time frame
safety;	—

Secondary

Measure	Time frame
SpO2;liver and kidney functions;myocardial biochemical marker;	—

Countries

China

Contacts

Public ContactFu zhou

Children's Hospital of Chongqing Medical University

fu_zhou79@126.com+86 13983021280

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026